Study on the Effect of Shenqi Lixin Decoction Combined with Dapagliflozin on Heart Failure after Direct PCI for A-cute Myocardial Infarction
Objective To investigate the effect of Shenqi Lixin Decoction combined with dapagliflozin on heart failure(HF)after direct percutaneous coronary intervention(PCI)in patients with acute myocardial infarction(AMI).Methods A total of 150 patients with HF after direct PCI of AMI in the emergency department of our hospital from March 2021 to March 2023 were includ-ed in the study.According to the treatment plan,they were divided into control group and combined group,with 75 cases in each group.The control group received routine treatment+dapagliflozin;the combined group received conventional treatment+dapa-gliflozin+Shenqi Lixin Decoction.All patients were treated for 3 months.The ultrasonic indexes of cardiac function[including end-systolic left ventricular diameter(LVESD),left ventricular mass index(LVMI),end-diastolic left ventricular volume(LV-EDV),left ventricular remodeling index(LVRI),end-diastolic left ventricular diameter(LVEDD),ejection fraction(LVEF)],serum microRNA levels[including miR-155,miR 208 a,miR-302 b],N-terminal pro-brain natriuretic peptide(NT-proBNP),6-minute walk test(6 MWT),major adverse cardiovascular events(MACE),quality of life(MLHF)and adverse reactions were statistically analyzed before treatment,at discharge and 3 months after treatment in the two groups.Results After treatment(at discharge and 3 months after treatment),LVESD,LVMI,LVEDV,LVRI and LVEDD in the two groups were lower than those before treatment(P<0.05),and LVEF was higher than that before treatment(P<0.05).The above indexes in the combined group were better than those in the control group(P<0.05).The levels of miR-155,miR208 a and miR-302 b in the two groups were lower than those before treatment(P<0.05),and the above indexes in the combined group were lower than those in the control group(P<0.05).The levels of NT-proBNP and 6MWT in the two groupswere higher than those before treat-ment,and the MLHF scores were lower than those before treatment(P<0.05),and the above indexes in the combined group were better than those in the control group(P<0.05).The total incidence of MACE events in the combined group was signifi-cantly lower than that in the control group(P<0.05).There was no significant difference in adverse reactions between the two groups(P>0.05).Conclusion For patients with HF after AMI direct PCI,Shenqi Lixin Decoction combined with dapagliflozin can effectively improve the clinical efficacy,cardiac function and ventricular remodeling without serious adverse reactions,which may be related to the regulation of miR-155,miR 208 a and miR-302 b levels.
万方数据
维普
